Regen BioPharma Inc (RGBP)

[cvinvestor]

From today's PR of TSOI

OCEANSIDE, CA--(Marketwired - May 09, 2016) - Therapeutic Solutions International, Inc., (OTC PINK: TSOI) announced today the signing of an exclusive license agreement between its subsidiary, MolecuVax, Inc., (MVAX) and UniVax, LLC covering composition of matter of a new cancer vaccine that targets a molecule found in cancer stem cells of a variety of types of cancers. The vaccine target, termed CTCFL or Brother of the Regulator of Imprinted Sites (BORIS), was discovered by researchers at the National Institutes of Health (NIH)[1], and has been shown in numerous peer-reviewed studies to be essential for cancer survival and progression[2],[3],[4].
"The patent covers vaccines that stimulate the immune system to selectively kill tumor cells that are expressing this universal "cancer specific" protein. In contrast to other vaccines, our vaccine is targeting BORIS protein that is critical for the growth of histologically different cancers. This possesses important implications in that if a cancer cell mutates to lose expression of the target, then the cancer cell will no longer be cancerous.

...

"After working on the concept of selectively killing cancer by immunologically targeting BORIS / CTCFL for over a decade, it is with great excitement to see this work translated from a scientific hypothesis, to issued US and International patents, and now on the road to commercialization and to patients," said Thomas Ichim, Ph.D, Board Member of TSOI. "In the past I was honored to have co-authored publications on BORIS / CTCFL with Dr. Agadjanyan and researchers at the NIH on this technology[7],[8],[9]. Now leveraging the infrastructure and expertise of MolecuVax, the time towards its clinical entry is rapidly approaching".